Anne Lesage Sells 10,600 Shares of Pharvaris (NASDAQ:PHVS) Stock

Key Points

• Insider selling: Pharvaris insider Anne Lesage sold 10,600 shares on June 29 at an average price of $35.07, bringing in about $371,742. Her holdings fell to 56,450 shares, a 15.81% decrease in her position.
• Multiple recent sales: Lesage also disclosed several additional share sales around the same period, including large transactions on June 30 totaling more than $2 million. The filings show a broader pattern of insider selling over the past few months.
• Stock and analyst backdrop: PHVS recently traded at $33.95, near its 12-month high of $35.90, after beating quarterly EPS estimates with a loss of $0.70 versus expectations of $0.82. Analysts remain generally positive, with a consensus rating of Moderate Buy and an average price target of $49.64.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Anne Lesage sold 10,600 shares of the business's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $35.07, for a total transaction of $371,742.00. Following the transaction, the insider directly owned 56,450 shares of the company's stock, valued at approximately $1,979,701.50. This represents a 15.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Anne Lesage also recently made the following trade(s):

• On Tuesday, June 30th, Anne Lesage sold 30,703 shares of Pharvaris stock. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47.
• On Tuesday, June 30th, Anne Lesage sold 27,872 shares of Pharvaris stock. The stock was sold at an average price of $35.48, for a total value of $988,898.56.
• On Monday, June 29th, Anne Lesage sold 6,997 shares of Pharvaris stock. The stock was sold at an average price of $35.05, for a total transaction of $245,244.85.
• On Wednesday, April 29th, Anne Lesage sold 3,700 shares of Pharvaris stock. The shares were sold at an average price of $30.08, for a total transaction of $111,296.00.
• On Thursday, April 30th, Anne Lesage sold 19,200 shares of Pharvaris stock. The shares were sold at an average price of $30.26, for a total transaction of $580,992.00.
• On Thursday, April 30th, Anne Lesage sold 21,700 shares of Pharvaris stock. The shares were sold at an average price of $30.26, for a total value of $656,642.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,000 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total value of $210,350.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,500 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $225,375.00.
• On Thursday, April 23rd, Anne Lesage sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total transaction of $3,003.00.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS traded down $0.63 during midday trading on Wednesday, reaching $33.95. 376,128 shares of the company's stock were exchanged, compared to its average volume of 409,202. The company's 50 day simple moving average is $30.90 and its two-hundred day simple moving average is $28.21. Pharvaris N.V. has a 12 month low of $17.05 and a 12 month high of $35.90. The firm has a market capitalization of $2.22 billion, a PE ratio of -10.68 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.82) by $0.12. On average, research analysts anticipate that Pharvaris N.V. will post -3.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PHVS has been the topic of a number of analyst reports. Citizens Jmp lowered their price target on Pharvaris from $75.00 to $74.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 13th. Wolfe Research started coverage on shares of Pharvaris in a research note on Thursday, April 9th. They issued an "outperform" rating and a $42.00 target price for the company. HC Wainwright reissued a "buy" rating on shares of Pharvaris in a report on Tuesday, June 16th. Wall Street Zen upgraded Pharvaris from a "sell" rating to a "hold" rating in a research report on Saturday, June 6th. Finally, Citigroup reaffirmed a "buy" rating on shares of Pharvaris in a report on Wednesday, April 15th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pharvaris presently has an average rating of "Moderate Buy" and a consensus price target of $49.64.

Institutional Trading of Pharvaris

A number of hedge funds and other institutional investors have recently modified their holdings of PHVS. Geode Capital Management LLC boosted its position in Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company's stock valued at $952,000 after buying an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock valued at $59,000 after acquiring an additional 783 shares during the last quarter. Legal & General Group Plc increased its position in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock worth $203,000 after purchasing an additional 1,695 shares during the period. Amundi raised its holdings in Pharvaris by 2,741,600.0% during the 2nd quarter. Amundi now owns 27,417 shares of the company's stock worth $489,000 after purchasing an additional 27,416 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Pharvaris by 19.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company's stock valued at $860,000 after purchasing an additional 7,879 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.